Trevena, Inc. (TRVN)
| Market Cap | 218.80M |
| Revenue (ttm) | 3.28M |
| Net Income (ttm) | -33.49M |
| Shares Out | 160.51M |
| EPS (ttm) | -0.23 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 30 |
| Last Price | $1.33 |
| Previous Close | $1.40 |
| Change ($) | -0.07 |
| Change (%) | -5.00% |
| Day's Open | 1.38 |
| Day's Range | 1.33 - 1.40 |
| Day's Volume | 2,073,874 |
| 52-Week Range | 1.33 - 3.68 |
TRV027 will be dosed in ~300 patients in nationwide trial led by Vanderbilt University Medical Center (VUMC) TRV027 will be dosed in ~300 patients in nationwide trial led by Vanderbilt University Medica...
Glass Lewis and Institutional Shareholder Services (ISS) independently recommend that Trevena shareholders vote “FOR” proposals to approve a Reverse Stock Split and concurrent Authorized Share Reduction...
Models demonstrate substantial overall cost savings for hospitals when using OLINVYK compared to IV morphine in postoperative care
Nhwa is conducting and funding this study to support NDA regulatory filing in China
-- Study is evaluating the role of age and weight in a comparative analysis of the effect of OLINVYK and morphine on respiratory function
Trevena (TRVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Trevena Inc (NASDAQ: TRVN) has announced that the National Institute on Drug Abuse (NIDA), part of the NIH, has resumed recruitment for its proof-of-concept study for TRV734. The Company has collaborate...
-- TRV734 reduced drug-seeking behavior in a preclinical model of relapse, suggesting its utility as a novel oral maintenance treatment for opioid use disorder
-- Models demonstrate substantial overall cost savings for hospitals when using OLINVYK compared to IV morphine in postoperative care
Trevena Inc's (NASDAQ: TRVN) TRV027 has been selected for an NIH ACTIV trial in COVID-19 patients that will be dosed in ~300 COVID-19 patients. TRV027 combats disruption within the renin-angiotensin-ald...
-- Vanderbilt University Medical Center (VUMC) is coordinating multiple-arm, multi-site ACTIV-4d study targeting RAAS
-- Company reaffirms YE target of 100 formulary approvals for OLINVYK®
Trevena Inc (NASDAQ: TRVN) has announced that its novel AT1 receptor-selective agonist, TRV027, has been selected for inclusion in an international Phase 2-Phase 3 trial in COVID-19 patients. The trial ...
-- REMAP-CAP is led by experts in pandemic response and builds upon a worldwide clinical trial network evaluating treatments for COVID-19
Trevena, Inc. Announces Presentations of OLINVYK™ Health Economic Models at AMCP 2021 Annual Meeting
-- Models demonstrate substantial overall cost savings for hospitals when using OLINVYK compared to IV morphine in postoperative care
These high-risk, high-reward healthcare stocks have outperformed the market over the past year.
Trevena (TRVN) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
Searching for stocks with above-average growth potential? Look no further.
-- Company to host conference call on March 9th, 2021, at 8:00 a.m. ET
-- Low incidence of respiratory depression observed with OLINVYK (oliceridine) injection regardless of age or body mass index, in exploratory analysis
Trevena's Catalyst-Filled Q1
CHESTERBROOK, Pa., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with centr...
-- P resentations highlight efficacy of TRV045 in animal models of neuropathic pain and epilepsy
-- OLINVYK s ignificantly reduced risk of vomiting and rescue antiemetic use compared to IV morphine in a retrospective analysis
OLINVYK is headed for commercial availability, likely by Q1 '21, even though distribution can occur as early as late November following DEA scheduling. Trevena still has a busy 2021 full of catalysts.
-- Guggenheim Healthcare Talks - 2nd Annual Neuro/Immunology Day Conference November 16 th Stifel Virtual Healthcare Conference November 1 8 th
-- OLINVYK commercial supply on track and available in November
Trevena (TRVN) will provide updates on its newly launched drug and other pipeline products when it releases its third-quarter 2020 results.
Is (TRVN) Outperforming Other Medical Stocks This Year?
-- Posters highlight improvements in respiratory safety and gastrointestinal tolerability associated with OLINVYK (oliceridine) injection vs. IV morphine
As of late, it has definitely been a great time to be an investor in Trevena.
-- Live presentation highlighting TRV027 as a potential treatment for COVID-19 acute respiratory distress syndrome (ARDS) / abnormal clotting
Investors need to pay close attention to Trevena (TRVN) stock based on the movements in the options market lately.
An analyst initiates coverage on the stock with an unequivocal buy recommendation.
- H.C. Wainwright: 22nd Annual Global Investment Conference - September 14th
Trevena: Strong Buy After Opioid Approval And Potential Supplementary COVID-19 Value
Trevena (NASDAQ: TRVN) shares are trading higher on Friday after Cantor Fitzgerald initiated coverage on the company's stock with an Overweight rating and announced a $5 price target.
-- Publication in Anesthesiology: Favorable benefit-risk profile for OLINVYK (oliceridine) injection as measured by clinical utility function analysis
Trevena (NASDAQ: TRVN) shares traded higher on Monday after the company announced the initiation of its TRV027 study in COVID-19 patients in collaboration with Imperial College London.
-- TRV027 is a novel AT1 receptor selective agonist with the potential to treat acute lung damage / abnormal blood clotting associated with COVID-19
-- $3 million milestone payment for U.S. approval of OLINVYK™ (oliceridine) injection
Investors need to pay close attention to Trevena (TRVN) stock based on the movements in the options market lately.
CHESTERBROOK, Pa., Aug. 14, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central ner...
The biopharmaceutical company announced the pricing of a public offering of common stock.
CHESTERBROOK, Pa., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) (“Trevena” or the “Company”), a biopharmaceutical company focused on the development and commercialization of novel me...
CHESTERBROOK, Pa., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with cen...
The biotech's innovative painkiller is the first new drug in its class in decades.
OLINVYK is a new chemical entity approved in adults for the management of acute pain severe enough to require an IV opioid analgesic
Trevena (TRVN) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Oliceridine is a new chemical entity intended for the management of moderate-to-severe acute pain Oliceridine is a new chemical entity intended for the management of moderate-to-severe acute pain
About TRVN
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agon... [Read more...]
| Industry Biotechnology | IPO Date Jan 31, 2014 |
| CEO Carrie Bourdow | Employees 25 |
| Stock Exchange NASDAQ | Ticker Symbol TRVN |
Financial Performance
In 2020, Trevena's revenue was $3.07 million, an increase of 9,800.00% compared to the previous year's $31,000. Losses were -$29.37 million, 18.1% more than in 2019.
Analyst Forecasts
According to 4 analysts, the average rating for Trevena stock is "Buy." The 12-month stock price forecast is 5.33, which is an increase of 300.75% from the latest price.